A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001)
A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001)
A phase I/II, randomized, single-blind, placebo-controlled escalating double-dose safety
 study of an intramuscular universal influenza vaccine (Multimeric-001) injected to healthy
 volunteers.
Inclusion Criteria:

 -  Healthy males and females between 18 and 55 years (inclusive) of age.

 -  Non-smoking (by declaration) for a period of at least 6 months.

 -  Subjects able to adhere to the visit schedule and protocol requirements and be
 available to complete the study.

 -  Haematology and Chemistry values within normal ranges or with no clinical significance

 -  Subjects who provide written informed consent to participate in the study

 Exclusion Criteria:

 -  Known history of significant medical disorder, which in the investigator's judgment
 contraindicates administration of the study medications.

 -  Ongoing flu symptoms or influenza

 -  Any clinically significant abnormality upon physical examination or in the clinical
 laboratory test at screening visit.

 -  Treatment with immune immunosuppressant drugs or other immune enhancing drugs.

 -  Subjects who have been immunized with anti-influenza vaccine or infected by influenza
 virus within one year prior to the screening visit.

 -  Administration of any vaccine 30 days before the screening visit.

 -  Known history of drug or alcohol abuse.

 -  Known history of HIV, hepatitis C or B virus (HCV or HBV)

 -  Subjects with known Guillain Barré Syndrome in the past

 -  2 or more hospitalization within the last year prior to screening visit

 -  Increased liver enzymes 2.5 times above the upper reference level

 -  Known hypersensitivity and/or allergy to any drugs

 -  Any acute medical situation (e.g. acute infection) within 48 hours of study start,
 which is considered of significance by the Principal Investigator.

 -  Subjects who participated in another clinical study within 30 days prior to study
 entry

 -  Subjects who are non-cooperative or unwilling to sign consent form.

 -  Pregnant or lactating women at entry to study and those that are unwilling to agree to
 continue precautions for two months after completion of the study